DefiniGEN

DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

3 June 2024 — Cambridge and Newcastle, UK — DefiniGEN and Atelerix today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix’s hydrogel preservation technology, which prevents loss of…

DefiniGEN Raises £1.5M ($2.29M USD) in Follow-on Funding

Cambridge, UK, 23rd May 2016: DefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The round was led by Cambridge Enterprise, the commercialization arm of the University of Cambridge, and 24 Haymarket, with key investors Dr Jonathan Milner (Chairman), Providence Investment Company, Parkwalk,…